Fei Xu

10PUBLICATIONS
22CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 19, 2026
Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors.

|Apr 15, 2026
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).

|Mar 02, 2026
Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial.

Xiaolu Xu, Jincai Zhong, Hong Lin

|Jan 02, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.

Ruo-Xi Hong, Fei Xu, Wen Xia

|Jun 13, 2024
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis.

Dongshao Chen, Fei Xu, Yongkui Lu

|Apr 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial.

Ying Chen, Wen-Xia Li, Jia-Hua Wu

Pageof 2

Frequent Collaborators

5 joint publications

Shusen Wang

3 joint publications

Kuikui Jiang

2 joint publications

Qiufan Zheng

2 joint publications

Ruoxi Hong